Medifast (MED) Q1 2026 earnings review
Productivity Spike Halts Revenue Slide, But Profits Evaporate
Medifast's revenue finally stopped falling sequentially, landing at $76 million in Q1. This stabilization occurred despite a severe 45% YoY collapse in the active coach network. The math works because the remaining 14,000 coaches became radically more efficient—driving a 19% YoY surge in revenue per coach. However, this volume contraction continues to crush unit economics. Gross margins contracted heavily, and Q1 operating losses would have been much worse without a one-time real estate sale. Guidance indicates the pain is far from over, with deep EPS losses projected for the rest of 2026.
🐂 Bull Case
The company's core leading indicator—revenue per active earning coach—is accelerating rapidly, hitting $5,432 (+19.2% YoY). This proves the new 'metabolic health' narrative is resonating with customers.
Medifast holds $168.9M in cash and zero debt. They have the financial runway to endure years of operating losses while attempting to execute this turnaround.
🐻 Bear Case
The absolute number of coaches is still in free-fall, dropping to 14,000 from 25,400 a year ago. Productivity gains cannot mathematically offset this level of churn forever.
Lower volumes are heavily penalizing gross margins (down to 68.1%). The business is deleveraging, forcing management to guide for steep, persistent net losses throughout 2026.
⚖️ Verdict: 🔴
Bearish. The sequential revenue stabilization is a much-needed green shoot, but the core growth engine (coach acquisition) is broken. With guidance pointing to a massive EPS loss in Q2, the turnaround remains theoretical.
Key Themes
Surging Coach Productivity
The most important data point in this report is the accelerating productivity of the remaining coaches. Average revenue per active earning coach hit $5,432, up 19.2% YoY. Management explicitly structured the network to prioritize productive leaders, and it is working. This metric historically leads network growth by 6 to 9 months, providing the only tangible mathematical hope for a 2027 top-line recovery.
Gross Margin Deleverage
Gross margin is decelerating badly, dropping to 68.1% from 72.8% a year ago. This 470 basis point collapse was explicitly blamed on the loss of leverage on fixed costs due to lower sales volumes. Until absolute unit volumes recover, Medifast will struggle to return to its historical mid-70s margin profile.
Real Estate Gain Masks True Operating Loss
The Q1 operating loss was reported at $3.3 million. However, SG&A expenses were reduced by a one-time $2.2 million gain from selling the Maryland Distribution Center. Without this non-recurring property sale, the true operating loss would have been $5.5 million. The core business is burning more cash than the headline EPS suggests.
The GLP-1 'Off-Ramp' Strategy
The rapid adoption of GLP-1 weight loss drugs caused Medifast's original crisis, but management is attempting a reversing maneuver: positioning Medifast as the solution for the high percentage of patients who quit GLP-1s due to side effects or cost. By focusing on 'Metabolic Synchronization' and lean muscle retention, they are targeting a massive, newly created demographic of former drug users seeking sustainable lifestyle habits.
Other KPIs
Decelerating aggressively. SG&A was cut by 35.6% YoY from $85.5 million. This was driven by a $16.2 million drop in coach compensation (tied directly to volume), $5.6 million less in corporate marketing, and $2.0 million in employee headcount reductions. Despite these massive cuts, SG&A actually increased as a percentage of revenue on an adjusted basis due to fixed cost deleveraging.
Stable. Up slightly from $167.3 million at the end of 2025. The company carries zero debt. This fortress balance sheet is Medifast's ultimate safety net, allowing them to fund the current operating losses without facing immediate liquidity crises.
Guidance
Decelerating sequentially. At the $70 million midpoint, this implies an 8% quarter-over-quarter decline from Q1's $76 million, signaling that the Q1 stabilization might be temporary rather than a definitive bottom.
Reversing sharply. Q1 posted a loss of just $0.19 per share. The midpoint of Q2 guidance (-$0.75) implies a severe deterioration in profitability in the immediate near term, confirming that Q1's relatively mild EPS loss was heavily padded by the $2.2M real estate sale.
Decelerating. This target confirms the narrative of a massive multi-year contraction compared to historical peaks. Achieving the midpoint ($285M) will require revenue to average roughly $70 million per quarter for the rest of the year.
Key Questions
Gross Margin Floor
Gross margins compressed by nearly 500 basis points due to fixed cost deleveraging. At what quarterly revenue run-rate do you expect gross margins to find a definitive floor?
Sustainability of Coach Productivity
Revenue per coach spiked an impressive 19% YoY. How much of this was driven by structural network improvements versus price increases or temporary Q1 promotions?
Active Coach Bottoming
The absolute number of coaches continues to fall rapidly (down 45% YoY). Based on your internal cohorts and the historical 6-9 month lag following productivity spikes, in which quarter do you expect absolute coach additions to turn positive?